**INFLAMMATORY BOWEL DISEASE SURVEY OF LASPGHAN MEMBERS**

The purpose of this survey is to collect data for an exploratory, epidemiologic study on inflammatory bowel disease (IBD) in Latin American children and adolescents, treated from 2005 to 2016, by members of the LASPGHAN. Information is requested on the number of cases treated per year, the total number of studies performed, the treatment prescribed in each of the types of IBD, and the gastrointestinal segments affected in ulcerative colitis and Crohn’s disease. It is important to make sure that the frequencies listed in the different sections of the survey coincide with one another.

**1.** City and country where you reside.

**Regarding the diagnosis of inflammatory bowel disease** (period from 2005 to 2016)

|  |  |  |
| --- | --- | --- |
| **2.** | How many patients have you treated that were **diagnosed with IBD**? |  |
| **3.** | How many patients were **diagnosed with ulcerative colitis**? |  |
| **4.** | How many patients were **diagnosed with Crohn’s disease**? |  |
| **5.** | How many patients were **diagnosed with inflammatory bowel disease unclassified**? |  |

1. Regarding **ulcerative colitis**: How many patients did you treat per year?

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |

1. Regarding **Crohn’s disease**: How many patients did you treat per year?

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |

1. Regarding **inflammatory bowel disease unclassified**:How many patients did you treat per year?

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 |

1. Indicate the number of times the following studies were performed to diagnose **inflammatory bowel disease**, from 2005 to 2016:

|  |  |
| --- | --- |
| a. Clinical data |  |
| b. Upper endoscopy |  |
| c. Upper endoscopy and biopsies of the esophagus, stomach, or duodenum |  |
| d. Colonoscopy |  |
| e. Colonoscopy and biopsies of the colon |  |
| f. Ileoscopy |  |
| g. Ileoscopy and biopsies of the terminal ileum |  |
| h. Imaging studies |  |
| Ulcerative colitis  |  |
| Crohn’s disease |  |
| Inflammatory bowel disease unclassified |  |
| i. Other |  |
|  j. If the answer was **Other**, indicate which study and the number of times it was performed. |

1. In treating **ulcerative colitis**: How many times were any of the following drugs prescribed?

(there can be more than one option)

|  |  |
| --- | --- |
| a. Intravenous corticosteroids  |  |
| b. Oral corticosteroids  |  |
| c. 5-aminosalicylic acid derivatives (sulfasalazine, mesalazine, etc.) |  |
| d. Azathioprine |  |
| e. 6-mercaptopurine |  |
| f. Infliximab, adalimumab, or another biologic agent |  |
| g. Other |  |
| h. If the answer was **Other**, indicate the drug and the number of times it was prescribed. |

1. In treating **Crohn’s disease**: How many times were any of the following drugs prescribed (there can be more than one option):

|  |  |
| --- | --- |
| a. Intravenous corticosteroids  |  |
| b. Oral corticosteroids  |  |
| c. 5-aminosalicylic acid derivatives (sulfasalazine, mesalazine, etc.) |  |
| d. Azathioprine |  |
| e. 6-mercaptopurine |  |
| f. Infliximab, adalimumab, or another biologic agent |  |
| g. Other |  |
| h. If the answer was **Other**, indicate the drug and the number of times it was prescribed. |

1. In treating **IBD unclassified** How many times were any of the following drugs prescribed? (there can be more than one option):

|  |  |
| --- | --- |
| a. Intravenous corticosteroids  |  |
| b. Oral corticosteroids |  |
| c. 5-aminosalicylic acid derivatives (sulfasalazine, mesalazine, etc.) |  |
| d. Azathioprine |  |
| e. 6-mercaptopurine |  |
| f. Infliximab, adalimumab, or another biologic agent |  |
| g. Other |  |
| h. If the answer was **Other**, indicate the drug and the number of times it was prescribed. |

1. Regarding **ulcerative colitis**, indicate the number of cases in which the following **segments were affected**:

|  |  |
| --- | --- |
| a. Rectosigmoid |  |
| b. Rectosigmoid and left colon  |  |
| c. Pancolitis |  |

1. Regarding **Crohn’s disease,** indicate the number of cases in which the following **segments were affected** (there can be more than one option):
	1. Upper gastrointestinal tract/mouth

|  |
| --- |
|  |
|  |
|  |

* 1. Small bowel
	2. Terminal ileum

|  |
| --- |
| d. Colon |
| e. Anus-rectum-perineum |